European Journal of Epidemiology

, Volume 15, Issue 5, pp 475–484

Epidemiological features of parainfluenza virus infections: Laboratory surveillance in England and Wales, 1975–1997

  • Henri Laurichesse
  • Daniel Dedman
  • John M. Watson
  • Maria C. Zambon
Article

Abstract

Hospital laboratory reports of parainfluenza virus (PIV) infections from England and Wales between 1975 and 1997 were analysed with regard to PIV type and seasonality, and in addition, those between 1985–1997 with regard to age, sex and clinical features. Laboratory-based surveillance data highlight striking differences in the seasonality of different PIV types. PIV-3 reports demonstrated a clear annual epidemic cycle, with a peak usually occurring in late spring or summer, whereas peaks of PIV-1 and PIV-2 occurred at one or two year intervals, in the late autumn or early winter. PIV-4 also occurred most frequently in the late autumn or early winter, but a clear epidemic cycle could not be identified. Laboratory surveillance data also provide insight into the age and disease distribution of PIV infection in children and indicate severity of PIV infection in immunosuppressed adults. Of 8221 PIV reports received between 1985–1997, PIV-3 accounted for 70.8, PIV-1 for 17.2, PIV-2 for 7.5, and PIV-4 for 1.1; 64.1 of reports came from infants under one year, 24.4 from children aged 1–4 years and 7.2 from individuals aged 5 years or older, with an excess of males in all age groups. Bronchiolitis, croup and pneumonia occurred in association with all PIV types. In children under 1 year, PIV-2 infections were more likely to be associated with bronchiolitis than infections with other PIV types. In children under 15 years, croup was more frequently associated with PIV-1 and PIV-2 than with PIV-3 or PIV-4. In 392 (7.2) of the reported PIV infections between 1989 and 1997 an underlying condition was implicated, which included immunosuppression or chronic cardiac or pulmonary disease. Considerable morbidity is associated with PIV infections in infants and young children and would make the widescale use of a vaccine a valuable public health intervention. Surveillance information is essential to guide the development and use of preventive measures as well as to monitor their effectiveness.

Epidemiology Parainfluenza virus Respiratory diseases Seasonality Surveillance 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436–1442.Google Scholar
  2. 2.
    Henrickson KJ. Lower respiratory viral infections in immunocompetent children. In: Aronoff SC (ed), Advances in paediatric infectious diseases. St. Louis: Mosby, 1994; 9: 59–96.Google Scholar
  3. 3.
    Suara RO, Glezen WP. Contribution of respiratory viruses to the world-wide problem of pneumonia in young children. Sem Pediatric Inf Dis 1995; 6: 121–127.Google Scholar
  4. 4.
    Leogrande G. Studies on the epidemiology of child infections. 3. Parainfluenza viruses (types 1–4) and respiratory syncytial virus infections. Microbios 1992; 72: 55–63.Google Scholar
  5. 5.
    Chanock RM. Association of a new type of cytopathogenic myxovirus with infantile croup. J Exp Med 1956; 104: 555–576.Google Scholar
  6. 6.
    Chanock RM, Parrot RH, Cook K, Andrews BE, Bell JA, Reichelderfer T, Kapikian AZ, Mastrota FM, Huebner RJ. Newly recognized myxoviruses from children with respiratory diseases. N Engl J Med 1958; 258: 207–213.Google Scholar
  7. 7.
    Johnson K, Chanock RM, Cook MK, Hyebner RJ. Studies of a new human hemadsorption virus. I. Isolation, properties and characterization. Am J Hyg 1960; 71: 81–92.Google Scholar
  8. 8.
    Vainiopaa R, Hyppia T. Biology of parainfluenza viruses. Clin. Microbiol Rev 1994; 7: 265–275.Google Scholar
  9. 9.
    Henrickson K, Ray R, Belshe R. Parainfluenza virus. In: Mandell GL, Benett JE, Dolin R (eds), Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th edn. New York: Churchill Livingstone, 1995: 1489–1496.Google Scholar
  10. 10.
    Lindquist SW, Darnule A, Istas A, Demmier GJ. Parainfluenza virus type 4 infections in pediatric patients. Pediatr Inf Dis J 1997; 16: 34–38.Google Scholar
  11. 11.
    Rubin EE, Quennec P, McDonald JC. Infections due to parainfluenza virus type 4 in children. Clin Infect Dis 1993; 17: 998–1002.Google Scholar
  12. 12.
    Karron RA, O'Brien KL, Froehlich JL, Brown VA. Molecular epidemiology of a parainfluenza type 3 virus outbreak on a Pediatric ward. J Infect Dis 1993; 167: 1441–1445.Google Scholar
  13. 13.
    Glasgow KW, Tamblyn SE, Blair G. A respiratory outbreak due to parainfluenza virus type 3 in a home for the aged, Ontario. Canada Commun Dis Rep 1995; 21: 57–61.Google Scholar
  14. 14.
    Zambon MC, Bull T, Sadler CS, Goldman JM, Ward KN. Molecular epidemiology of two consecutive outbreaks of parainfluenza 3 infection in a Bone Marrow Transplant Unit. J Clin Micro 1998: 2289–2293.Google Scholar
  15. 15.
    Wendt CH, Hertz MI. Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host. Sem Resp Inf 1995; 10: 224–231.Google Scholar
  16. 16.
    Wall PG, de Louvois J, Gilbert RJ, Rowe B. Food poisoning: Notifications, laboratory reports, and outbreaks — where do they come from and what do they mean? Comm Dis Report CDR Review 1996; 7: R93–100.Google Scholar
  17. 17.
    Grant AD, Eke B. Application of information technology to the laboratory reporting of communicable disease in England and Wales. Commun Dis Rep CDR Rev 1993; 3: R75–78.Google Scholar
  18. 18.
    Reed G, Jewett PH, Thompson J, Tollefson S, Wright PF. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 years old. J Infect Dis 1997; 175: 807–813.Google Scholar
  19. 19.
    Marx A, Török TJ, Holman RC, Clarcke MJ, Anderson LJ. Pediatric hospitalizations for croup (laryngotracheobronchitis): Biennial increases associated with human parainfluenza virus 1 epidemics. J Infect Dis 1997; 176: 1423–1427.Google Scholar
  20. 20.
    Glezen WP, Franck AL, Taber LH, Kasel JA. Parainfluenza virus type 3: Seasonality and reinfection in young children. J Infect Dis 1984; 150: 851–857.Google Scholar
  21. 21.
    Easton AJ, Eglin RP. Epidemiology of parainfluenza virus type 3 in England and Wales over a ten-year period. Epidemiol Inf 1989; 102: 531–535.Google Scholar
  22. 22.
    Centers for Disease Control. Respiratory syncytial virus and parainfluenza virus surveillance, United States, 1989–90. MMWR 1990; 39: 832–834.Google Scholar
  23. 23.
    de Silva LM, Cloonan MJ. Parainfluenza virus type 3 infections: Findings in Sydney and some observations on variations in seasonality world-wide (Brief report). J Med Virol 1991; 35: 19–21.Google Scholar
  24. 24.
    Welliver R, Wong DT, Choi TS, Ogra PL. Natural history of parainfluenza virus infection in childhood. J Pediatr 1982; 101: 180–187.Google Scholar
  25. 25.
    Parrott RH, Vargosko AJ, Kim WH, Bell JA, Chanock RM. Acute respiratory diseases of viral aetiology. III. Myxoviruses: Parainfluenza. Am J Public Health 1962; 52: 907–917.Google Scholar
  26. 26.
    Denny FW, Murphy TF, Clyde WA Jr., Collier AM, Henderson FW. Croup: An 11–year study in a Pediatric practice. Pediatrics 1983; 71: 871–876.Google Scholar
  27. 27.
    Foy HM, Cooney MK, Maletzky AJ, Grayston JT. Incidence and aetiology of pneumonia, croup and bronchiolitis in pre-school children belonging to a prepaid medical care group over a four-year period. Am J Epidemiol 1973; 97: 80–92.Google Scholar
  28. 28.
    Knott AM, Long CE, Breese Hall C. Parainfluenza viral infections in Pediatric outpatients: Seasonal patterns and clinical characteristics. Pediatr Infect Dis J 1994; 13: 269–273.Google Scholar
  29. 29.
    Arisoy ES, Demmler GJ, Thakar S, Doerr C. Meningitis due to parainfluenza virus type 3: Report of two cases and review. Clin Infect Dis 1993; 17: 995–997.Google Scholar
  30. 30.
    Craver RD, Gohd RS, Sundin DR, Hierholzer JC. Isolation of parainfluenza virus type 3 from cerebrospinal fluid associated with aseptic meningitis. Am J Clin Path 1993; 99: 705–707.Google Scholar
  31. 31.
    Jantausch BA, Wiedermann BL, Jeffries B. Parainfluenza virus type 2 meningitis in an 11–old child. South Med J 1995; 88: 230–231.Google Scholar
  32. 32.
    Jackson MA, Olson LC, Burry VF. Parainfluenza virus and neurologic signs. Pediatr Inf Dis J 1994; 13: 759–760.Google Scholar
  33. 33.
    Sable CA, Hayden FG. Orthomyxoviral and para-myxoviral infections in transplant patients. Infect Dis Clin North Am 1995; 9: 987–1003.Google Scholar
  34. 34.
    Couch RB, Englund JA, Whimbley E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med 1997; 102(3A): 2–9.Google Scholar
  35. 35.
    Wendt CH. Community respiratory viruses: Organ transplant recipients. Am J Med 1997; 102(3A): 31–36.Google Scholar
  36. 36.
    King JC. Community respiratory viruses in individuals with human immunodeficiency virus infection. Am J Med 1997; 102(3A): 19–24.Google Scholar
  37. 37.
    Wendt CH, Weisdorf DJ, Jordan MC, Balfour HH Jr., Hertz MI. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med 1992; 326: 921–926.Google Scholar
  38. 38.
    Whimbey E, Vartivarian SE, Champlin RE, Elting LS, Luna M, Bodey GP. Parainfluenza virus infection in adult bone marrow transplant recipients. Eur J Clin Microl Infect Dis 1993; 12: 699–701.Google Scholar
  39. 39.
    Lewis VA, Champlin R, Englund J, Couch R, Goodrich JM, Rolsten K, Przepiorka D, Mirza NQ, Yousef HM, Luna M, Bodey GP, Whimbey E. Respiratory disease due to parainfluenza virus in adults bone marrow transplant recipients. Clin Infect Dis 1996; 23: 1033–1037.Google Scholar
  40. 40.
    Whimbley E, Englund JA, Couch RB. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med 1997; 102(3A): 10–18.Google Scholar
  41. 41.
    Bowden RA. Respiratory virus infections after marrow transplants: The Fred Hutchinson Cancer Research Center Experience. Am J Med 1997; 102(3A): 27–30.Google Scholar
  42. 42.
    Ljungman P. Respiratory virus infections in bone marrow transplant recipients: The European perspective. Am J Med 1997; 102(3A): 44–47.Google Scholar
  43. 43.
    Wendt CH. Community respiratory viruses: Organ transplants recipients. Am J Med 1997; 102(3A): 31–36.Google Scholar
  44. 44.
    Apalsch AM, Green M, Ledesma-Medina J, Nour B, Wald ER. Parainfluenza and influenza virus infections in Pediatric organ transplant recipients. Clin Infect Dis 1995; 20: 394–399.Google Scholar
  45. 45.
    Wendt CH, Fox JM, Hertz MI. Paramyxovirus infection in lung transplant recipients. J Heart Lung Transplant 1995; 14: 479–485.Google Scholar
  46. 46.
    Cobian L, Houston S, Greene J, Sinnott JT. Parainfluenza virus respiratory infection after heart transplant: Successful treatment with ribavirin. Clin Infect Dis 1995; 21: 1040–1041.Google Scholar
  47. 47.
    Avery RK, Longworth DL. Viral pulmonary infections in thoracic and cardiovascular surgery. Sem Thoracic & Cardiovascular Surg 1995; 7: 88–94.Google Scholar
  48. 48.
    PHLS-CDSC. Parainfluenza infections in the elderly. Br Med J 1983; 287: 1976–1982.Google Scholar
  49. 49.
    Henrickson KJ, Kuhn SM, Savatski LL. Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children. Clin Infect Dis 1994; 18: 770–779.Google Scholar
  50. 50.
    Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitami M, Meiklejohn G. Respiratory virus immunization. 1. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969; 89: 435–448.Google Scholar
  51. 51.
    Chin J, Magoffin RI, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a Pediatric population. Am J Epidemiol 1969; 89: 449–463.Google Scholar
  52. 52.
    Ambrose MW, Wyde PR, Ewasyshyn M, Bonneau AM, Caplan B, Meyer HL, Klein M. Evaluation of the immunogenicity and protective efficacy of a candidate parainfluenza virus type 3 subunit vaccine in cotton rats. Vaccine 1991; 9: 505–511.Google Scholar
  53. 53.
    Karron RA, Wright PF, Hall SL, Makhene M, Thompson J, Burns BA, Tollefson S, Steinhoff MC, Wilson MH, Harris DO, et al. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis 1995; 171: 1107–1114.Google Scholar
  54. 54.
    Karron RA, Wright PF, Newman FK, Makhene M, Thompson J, Samorodin R, Wilson MH, Anderson EL, Clements ML, Murphy BR, et al. A live human parainfluenza type 3 virus is attenuated and immunogenic in healthy infants and children. J Infect Dis 1995; 172: 1445–1450.Google Scholar
  55. 55.
    Anonymous. Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: Memorandum from a Joint WHO/NIAID meeting. Bul WHO 1997; 75: 307–313.Google Scholar
  56. 56.
    Beekmann SE, Engler HD, Collins AS, Canosa J, Henderson DK, Freifeld A. Rapid identification of respiratory viruses: Impact on isolation practices and transmission among immunocompromised Pediatric patients. Infect Control & Hosp Epidemiol 1996; 17: 581–586.Google Scholar
  57. 57.
    Garner JS, and the Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol 1996; 17: 54–80.Google Scholar
  58. 58.
    Englund JA, Piedra PA, Whimbey E. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am J Med 1997; 102(3A): 61–70.Google Scholar
  59. 59.
    Raad I, Abbas J, Whimbley E. Infection control of nosocomial respiratory viral disease in the immunocompromised host. Am J Med 1997; 103(A): 48–52.Google Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Henri Laurichesse
    • 1
  • Daniel Dedman
    • 1
  • John M. Watson
    • 1
  • Maria C. Zambon
    • 2
  1. 1.Epidemiology Division, Communicable Disease Surveillance Centre (CDSC)Public Health Laboratory Service, ColindaleLondonUK
  2. 2.Enteric and Respiratory Virus Laboratory, Central Public Health Laboratory (CPHL), Public Health Laboratory Service, ColindaleLondonUK
  3. 3.Service des Maladies Infectieuses et Tropicales, Hotel Dieu/CHU de Clermont-FerrandClermont-FerrandFrance
  4. 4.Department of Social Medicine, Canynge HallUniversity of BristolBristolUK

Personalised recommendations